Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.61 |
| ▸ | CDK4 | P11802 | 18/20 | 0.61 |
| ▸ | CCND1 | P24385 | 18/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.61 |
| ▸ | CCND3 | P30281 | 5/20 | 0.61 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.59 |
| ▸ | CDK9 | P50750 | 3/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.59 |
| ▸ | CDK1 | P06493 | 1/20 | 0.59 |
| ▸ | CDK7 | P50613 | 1/20 | 0.59 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.59 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22569947 | 1.00 | CDK2 (0.61) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22570197 | 0.95 | CDK2 (0.67) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551670 | 0.95 | CDK2 (0.67) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22569948 | 0.94 | CDK2 (0.69) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551690 | 0.94 | CDK2 (0.69) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551668 | 0.93 | CDK2 (0.68) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551658 | 0.93 | CDK2 (0.68) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551709 | 0.91 | CDK2 (0.64) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22570138 | 0.91 | CDK2 (0.70) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22570278 | 0.91 | CDK2 (0.70) | CDK2CDK4CCND1CCNE1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | MKI67, CCNC, CCNI | CDK2 17/4885CDK4 4/4885CCND1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.